Pictet Asset Management
SRPT icon

Pictet Asset Management’s Sarepta Therapeutics SRPT Stock Holding History

Pictet Asset Management’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$278K Hold
15,482
– – ﹤0.01% 1808
2026
Q1 		$337K Buy
15,482
+2,347
+18% +$45.4K ﹤0.01% 1662
2025
Q4 		$283K Hold
13,135
– – ﹤0.01% 1741
2025
Q3 		$253K Sell
13,135
-165,516
-93% -$2.95M ﹤0.01% 1749
2025
Q2 		$3.06M Sell
178,651
-758,372
-81% -$32.4M ﹤0.01% 833
2025
Q1 		$60.7M Sell
937,023
-109,002
-10% -$11.5M 0.07% 276
2024
Q4 		$127M Sell
1,046,025
-4,986
-0.5% -$611K 0.14% 174
2024
Q3 		$131M Buy
1,051,011
+93,793
+10% +$13M 0.14% 172
2024
Q2 		$151M Sell
957,218
-301,318
-24% -$38.7M 0.17% 145
2024
Q1 		$163M Buy
1,258,536
+166,934
+15% +$20.4M 0.18% 150
2023
Q4 		$105M Buy
1,091,602
+126,658
+13% +$12.2M 0.12% 198
2023
Q3 		$117M Buy
+964,944
New +$109M 0.14% 177

Other funds holding SRPT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Pictet Asset Management's SRPT Position: Q2 2026 in Review

Pictet Asset Management held its Sarepta Therapeutics (SRPT) position steady in Q2 2026 at 15,482 shares worth $278K. The position accounts for ﹤0.01% of the portfolio, ranked #1808.

Pictet Asset Management first reported a position in SRPT in Q3 2023 and has held it in 12 quarters since. The position peaked at $163M in Q1 2024. 324 funds tracked by Wall St. Rank hold SRPT as of Q2 2026.

  • Pictet Asset Management held 15,482 shares of Sarepta Therapeutics worth $278K as of Q2 2026.
  • Pictet Asset Management left its Sarepta Therapeutics share count unchanged in Q2 2026.
  • Sarepta Therapeutics made up ﹤0.01% of Pictet Asset Management's portfolio in Q2 2026, its #1808 holding.
  • Pictet Asset Management first reported a position in Sarepta Therapeutics in Q3 2023 and has held it in 12 quarters since.
  • Pictet Asset Management's Sarepta Therapeutics position peaked at $163M in Q1 2024.
  • 324 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2026.

Based on Pictet Asset Management's 13F filing for Q2 2026, filed 30 Jul 2026.